Please enable JavaScript to continue using this application.

Compare $ANNX vs $CADL | Chartloom

Compare

$ANNX vs $CADL

Annexon Inc · Candel Therapeutics Inc

ANNX

Annexon Inc

CADL

Candel Therapeutics Inc

Compare $ANNX vs $CADL

Comparing Annexon Inc and Candel Therapeutics Inc

ANNXAnnexon Inc

CADLCandel Therapeutics Inc

ANNXAnnexon Inc

Market cap

$659M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.66x

Rev growth (TTM)

—

YTD performance

-14.3%

52W performance

27.6%

FCF yield

-29.3%

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANNX

CADL

Detailed metrics comparison

ANNX

Annexon Inc

CADL

Candel Therapeutics Inc

Market Cap

ANNX$659M

CADL$728M

Enterprise Value

ANNX$459M

CADL$575M

Price

ANNX$4.02

CADL$9.94

P/E Ratio

ANNXN/A

CADLN/A

P/S Ratio

ANNX0.00x

CADL6,281.93x

EV/Sales

ANNX0.00x

CADL5,042.14x

EV/EBITDA

ANNX0.00x

CADL0.00x

P/B Ratio

ANNX4.27x

CADL6.18x

P/FCF Ratio

ANNXN/A

CADLN/A

EV/FCF

ANNX-2.38x

CADL-10.02x

PEG Ratio

ANNXN/A

CADLN/A

Forward P/E (NTM)

ANNXN/A

CADLN/A

Forward P/S (NTM)

ANNX21.66x

CADLN/A

Revenue (TTM)

ANNX$0

CADL$0

Revenue Growth (YoY)

ANNXN/A

CADLN/A

Forward Rev Growth

ANNX370.6%

CADL371.1%

Gross Margin (TTM)

ANNX0.0%

CADL0.0%

Operating Margin (TTM)

ANNX0.0%

CADL0.0%

EBITDA Margin (TTM)

ANNX0.0%

CADL0.0%

Net Margin (TTM)

ANNX0.0%

CADL0.0%

FCF Margin (TTM)

ANNXN/A

CADLN/A

Net Income (TTM)

ANNX$-203M

CADL$-89M

FCF (TTM)

ANNX$-193M

CADL$-57M

EPS (TTM)

ANNX-$1.01

CADL-$1.19

ROE (TTM)

ANNX-10615.0%

CADL-8938.0%

ROA (TTM)

ANNX-7982.0%

CADL-5631.0%

ROIC (TTM)

ANNX-10615.0%

CADL-6512.0%

Cash

ANNX$199M

CADL$202M

Debt

ANNX$0

CADL$48M

Net Cash/Debt

ANNX$199M

CADL$154M

Current Ratio (TTM)

ANNX5.53x

CADL16.09x

Quick Ratio (TTM)

ANNX5.44x

CADL15.89x

Debt/Equity (TTM)

ANNX0.00x

CADL0.38x

Debt/Assets (TTM)

ANNX0.0%

CADL0.0%

Interest Coverage (TTM)

ANNXN/A

CADLN/A

Net Debt/EBITDA (TTM)

ANNX0.00x

CADL0.00x

Beta

ANNX1.40

CADL-0.28

52W Performance

ANNX27.6%

CADL57.8%

YTD Performance

ANNX-14.3%

CADL82.7%

% from 52W High

ANNX-44.0%

CADL-29.0%

% from 52W Low

ANNX58.3%

CADL128.5%

Asset Turnover (TTM)

ANNX0.00x

CADL0.00x

FCF Yield (TTM)

ANNX-29.3%

CADL-7.9%

Earnings Yield (TTM)

ANNX-30.8%

CADL-12.2%

Dividend Yield (TTM)

ANNXN/A

CADLN/A

Rule of 40

ANNX0.0

CADL0.0

EV/GP/RG

ANNXN/A

CADLN/A

Ticker research

View ANNX research View CADL research

Metric	ANNX Annexon Inc	CADL Candel Therapeutics Inc
Market & Valuation
Market Cap	$659M	$728M
Enterprise Value	$459M	$575M
Price	$4.02	$9.94
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	6,281.93x
EV/Sales	0.00x	5,042.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.27x	6.18x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.38x	-10.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.66x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	370.6%	371.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-203M	$-89M
FCF (TTM)	$-193M	$-57M
EPS (TTM)	-$1.01	-$1.19
ROE (TTM)	-10615.0%	-8938.0%
ROA (TTM)	-7982.0%	-5631.0%
ROIC (TTM)	-10615.0%	-6512.0%
Financial Health
Cash	$199M	$202M
Debt	$0	$48M
Net Cash/Debt	$199M	$154M
Current Ratio (TTM)	5.53x	16.09x
Quick Ratio (TTM)	5.44x	15.89x
Debt/Equity (TTM)	0.00x	0.38x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	-0.28
52W Performance	27.6%	57.8%
YTD Performance	-14.3%	82.7%
% from 52W High	-44.0%	-29.0%
% from 52W Low	58.3%	128.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-29.3%	-7.9%
Earnings Yield (TTM)	-30.8%	-12.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANNX research	View CADL research

Valuation

P/S Ratio

ANNX

0.00x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

ANNX

-2.38x

Growth & revenue

Forward Revenue Growth

CADL

371.1%

ANNX

370.6%

Profitability & performance

Gross Margin

ANNX

0.0%

CADL

0.0%

ROE

CADL

-8938.0%

ANNX

-10615.0%

FCF Yield %

CADL

-7.9%

ANNX

-29.3%

52-Week Performance

CADL

57.8%

ANNX

27.6%

Detailed metrics comparison

ANNX

Annexon Inc

CADL

Candel Therapeutics Inc

Market Cap

ANNX$659M

CADL$728M

Enterprise Value

ANNX$459M

CADL$575M

Price

ANNX$4.02

CADL$9.94

P/E Ratio

ANNXN/A

CADLN/A

P/S Ratio

ANNX0.00x

CADL6,281.93x

EV/Sales

ANNX0.00x

CADL5,042.14x

EV/EBITDA

ANNX0.00x

CADL0.00x

P/B Ratio

ANNX4.27x

CADL6.18x

P/FCF Ratio

ANNXN/A

CADLN/A

EV/FCF

ANNX-2.38x

CADL-10.02x

PEG Ratio

ANNXN/A

CADLN/A

Forward P/E (NTM)

ANNXN/A

CADLN/A

Forward P/S (NTM)

ANNX21.66x

CADLN/A

Revenue (TTM)

ANNX$0

CADL$0

Revenue Growth (YoY)

ANNXN/A

CADLN/A

Forward Rev Growth

ANNX370.6%

CADL371.1%

Gross Margin (TTM)

ANNX0.0%

CADL0.0%

Operating Margin (TTM)

ANNX0.0%

CADL0.0%

EBITDA Margin (TTM)

ANNX0.0%

CADL0.0%

Net Margin (TTM)

ANNX0.0%

CADL0.0%

FCF Margin (TTM)

ANNXN/A

CADLN/A

Net Income (TTM)

ANNX$-203M

CADL$-89M

FCF (TTM)

ANNX$-193M

CADL$-57M

EPS (TTM)

ANNX-$1.01

CADL-$1.19

ROE (TTM)

ANNX-10615.0%

CADL-8938.0%

ROA (TTM)

ANNX-7982.0%

CADL-5631.0%

ROIC (TTM)

ANNX-10615.0%

CADL-6512.0%

Cash

ANNX$199M

CADL$202M

Debt

ANNX$0

CADL$48M

Net Cash/Debt

ANNX$199M

CADL$154M

Current Ratio (TTM)

ANNX5.53x

CADL16.09x

Quick Ratio (TTM)

ANNX5.44x

CADL15.89x

Debt/Equity (TTM)

ANNX0.00x

CADL0.38x

Debt/Assets (TTM)

ANNX0.0%

CADL0.0%

Interest Coverage (TTM)

ANNXN/A

CADLN/A

Net Debt/EBITDA (TTM)

ANNX0.00x

CADL0.00x

Beta

ANNX1.40

CADL-0.28

52W Performance

ANNX27.6%

CADL57.8%

YTD Performance

ANNX-14.3%

CADL82.7%

% from 52W High

ANNX-44.0%

CADL-29.0%

% from 52W Low

ANNX58.3%

CADL128.5%

Asset Turnover (TTM)

ANNX0.00x

CADL0.00x

FCF Yield (TTM)

ANNX-29.3%

CADL-7.9%

Earnings Yield (TTM)

ANNX-30.8%

CADL-12.2%

Dividend Yield (TTM)

ANNXN/A

CADLN/A

Rule of 40

ANNX0.0

CADL0.0

EV/GP/RG

ANNXN/A

CADLN/A

Ticker research

View ANNX research View CADL research

Metric	ANNX Annexon Inc	CADL Candel Therapeutics Inc
Market & Valuation
Market Cap	$659M	$728M
Enterprise Value	$459M	$575M
Price	$4.02	$9.94
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	6,281.93x
EV/Sales	0.00x	5,042.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.27x	6.18x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.38x	-10.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.66x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	370.6%	371.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-203M	$-89M
FCF (TTM)	$-193M	$-57M
EPS (TTM)	-$1.01	-$1.19
ROE (TTM)	-10615.0%	-8938.0%
ROA (TTM)	-7982.0%	-5631.0%
ROIC (TTM)	-10615.0%	-6512.0%
Financial Health
Cash	$199M	$202M
Debt	$0	$48M
Net Cash/Debt	$199M	$154M
Current Ratio (TTM)	5.53x	16.09x
Quick Ratio (TTM)	5.44x	15.89x
Debt/Equity (TTM)	0.00x	0.38x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	-0.28
52W Performance	27.6%	57.8%
YTD Performance	-14.3%	82.7%
% from 52W High	-44.0%	-29.0%
% from 52W Low	58.3%	128.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-29.3%	-7.9%
Earnings Yield (TTM)	-30.8%	-12.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANNX research	View CADL research